Biotechnology company focused on discovering and developing therapies targeting chromatin regulatory proteins.
Foghorn Therapeutics Inc. is an advanced-stage biopharmaceutical company specializing in the discovery and development of therapies that target genetically determined dependencies within the chromatin regulatory system. Leveraging its proprietary Gene Traffic Control platform, the company identifies, validates, and potentially drugs targets within this system to address challenging medical conditions.
At the forefront of its pipeline is FHD-286, a small molecule inhibitor designed to target the enzymatic activity of BRG1 and BRM. This candidate holds promise for treating metastatic uveal melanoma, as well as relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome. Additionally, Foghorn Therapeutics is advancing FHD-609, a small molecule protein degrader aimed at BRD9,a, with potential applications in treating patients with synovial sarcoma.
The company's innovative research extends to developing enzymatic inhibitors and protein degraders as selective modulators of BRM, as well as ARID1B selective modulators intended for treating ovarian, endometrial, colorectal, bladder, and gastric cancers. Collaborative efforts with Merck Sharp & Dohme Corp. and Loxo Oncology underscore Foghorn's commitment to advancing oncology therapeutics. These partnerships focus on discovering and developing novel medicines against transcription factor targets.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Foghorn Therapeutics continues to expand its scientific capabilities and therapeutic pipeline. With a robust portfolio of innovative treatments and strategic collaborations, the company is poised to make significant contributions to the field of chromatin biology and precision medicine.